Abstract. Cetuximab, an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody (mAb), is a novel targeted therapy for the treatment of patients with oral cancer. Cetuximab can be used in combination with chemotherapeutic agents to prolong the overall survival rates of patients with oral cancer. Curcumin is a traditional Chinese medicine, and it has been demonstrated to have growth-inhibiting effects on oral cancer cells. However, information regarding the combination of cetuximab and curcumin in drug-resistant oral cancer cells is lacking, and its underlying mechanism remains unclear. The purpose of the present study was to explore the oral anticancer effects of cetuximab combined with curcumin on cisplatin-resistant oral cancer CAR cell apoptosis

The results demonstrated that co-treatment with cetuximab and curcumin exerts synergistic oral anticancer effects on CAR cells through the suppression of the EGFR signaling by regulation of the MAPK pathway.

Introduction

Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase in the cell transmembrane that serves an essential role in proliferation, metastasis, angiogenesis and chemo-resistance of oral cancer cells (1,2). More than 80% patients with oral cancer and oral cancer cell lines exhibit overexpression of EGFR (3-6). High expression of EGFR protein in oral cancer is associated with poor prognosis, decreased survival time and increased metastatic potential (7,8). Inhibition of EGFR and regulation of downstream signaling represents a novel approach for oral cancer therapy (9,10). Various strategies have been developed to disrupt EGFR function and to interfere with downstream signaling (11,12). Anti-EGFR mAbs and EGFR inhibitors have been investigated the most extensively (3,5,13).

Cetuximab is an EGFR-targeting mAb and the first novel targeted agent for oral cancer treatment to obtain Food and Drug Administration approval in the United States (11,13). In combination with chemotherapeutic agents, cetuximab has been demonstrated to increase the overall survival rate of patients with oral cancer, and to have less toxicity (7,10,14). In oral cancer therapy, combination of cetuximab with cisplatin, 5-fluorouracil (5-FU), docetaxel (Taxotere) or paclitaxel (Taxol) has become the new standard advanced treatment (8,9,15,16).

Curcumin is a traditional Chinese medicine isolated from the rhizome of Curcuma longa (17-20). Curcumin has been shown to exert anti-inflammatory, anti-oxidant, and anticancer effects, it is pharmacologically safe and has minimal toxicity (17,19,20). The anticancer activities of curcumin are attributable to its anti-proliferative, anti-angiogenic, anti-metastatic, pro-apoptotic and autophagic characteristics (21-25). In vitro studies reported that curcumin inhibited cell proliferation in various oral cancer
cell lines, including CAL 27, 1483, SCC-1, SCC-9, KB, SAS and SCC15 (26). Curcumin also suppressed EGFR expression and its downstream signaling molecules (NF-κB, JNK, p38 and ERK) which are vital for oral cancer pathogenesis (27-29). Furthermore, curcumin enhanced cisplatin cytotoxicity in PE/CA-P15 cells in vitro (30). The combination of 5-FU, doxorubicin or cisplatin with curcumin exhibited inhibited proliferation and induced apoptotic cell death of NT8e oral squamous cell carcinoma cells (31). However, the molecular mechanism of the suppression of cell proliferation and apoptotic induction of drug-resistant oral cancer cells following co-incubation with cetuximab and curcumin remains poorly understood. Herein, the synergistic effects and underlying molecular mechanism of the effect of combined treatment of cetuximab and curcumin in cisplatin-resistant oral cancer CAR cells was explored.

Materials and methods

Chemicals and reagents. Erbitux (the active ingredient of cetuximab) was provided by Hualien Tzu Chi Hospital (Taiwan) and originally purchased from Merck KGaA (Darmstadt, Germany). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), L-glutamine and penicillin-streptomycin solution were purchased from HyClone (GE Healthcare, Logan, UT, USA). Caspase-3 and Caspase-9 colorimetric assay kits were sourced from R&D Systems (Minneapolis, MN, USA). All primary antibodies and anti-mouse/rabbit immunoglobulin G (IgG) horseradish peroxidase (HRP)-conjugated antibodies were purchased from GeneTex (Hsinchu, Taiwan). Curcumin, Thiazolyl Blue Tetrazolium Bromide (MTT) and other reagents were of analytical grade from Sigma-Aldrich (Merck KGaA, Darmstadt Germany), unless otherwise stated.

Cell culture. The human oral cancer cell line, CAL 27, was obtained from American Type Culture Collection (ATCC; Manassas, VA, USA). The cisplatin-resistant subline of CAL 27, CAR, was generated in our laboratory, as previously described (32-34) and exposed to increasing concentrations of cisplatin to generate a stable subline with resistance ≥80 µM cisplatin. CAR cells were maintained in an environment of 5% CO2 at 37°C in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 µg/ml streptomycin, 100 Units/ml penicillin and 80 µM cisplatin. Cetuximab was diluted with culture medium (DMEM with supplementation as described above), and curcumin was dissolved in dimethyl sulfoxide (DMSO).

Cytotoxicity assay. Cell viability was estimated by MTT assay. In brief, CAR cells (1x10^6 cells/well) were plated in 96-well tissue culture plates and treated with curcumin (10, 20, 40 or 50 µM), cetuximab (10, 20, 40 or 50 µg/ml) or 20 µg/ml cetuximab and 10, 20 or 40 µM curcumin for 24 h. Following exposure and removal of the medium, the cells were cultured with 0.5 mg/ml MTT for an additional 2 h. The blue formazan product was dissolved in 100 µl DMSO and spectrophotometrically measured at a wavelength of 570 nm using an ELISA plate reader (Anthos Labtec Instruments GmbH, Salzburg, Austria), as previously described (35). The percentage of living cells was calculated, and the ratio of optical density of the experimental wells and control wells was calculated as % of control. Combination index (CI) was determined using the Chou-Talalay method, as previously described (36). A value <1.0 indicated a synergistic effect.

Morphological determination. CAR cells (1x10^6 cells per well) were seeded into a 24-well plate and treated with 20 µg/ml cetuximab and 10, 20 or 40 µM curcumin for 24 h. The cells were visualized using a phase-contrast microscope to check for apoptotic characteristics and photographed, as previously described (37).

Caspase-3 and -9 activity measurement. CAR cells were seeded at a density of 5x10^6 cells per 75T flask and incubated with 20 µg/ml cetuximab, 40 µM curcumin, or 20 µg/ml cetuximab and 40 µM curcumin for 24 h. The cell lysate was collected, and the cell fraction was analyzed for caspase-3/-9 activity using Caspase-3 and Caspase-9 Colorimetric Assay kits (R&D Systems, Inc., Minneapolis, MN, USA), according to the manufacturer's protocol.

Western blot analysis. CAR cells (5x10^6 cells per 75T flask) were treated with either 20 µg/ml cetuximab, 40 µM curcumin or both for 24 h. Then, the cells were harvested and lysed with PRO-PREP Protein Extraction Solution (iNtRON Biotechnology, Seongnam-si, Gyeonggi-do, Korea). The protein concentration was determined using the Pierce BCA protein assay kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA), and 40 µg protein was loaded per lane of 8-10% SDS-PAGE gels. The protein was thereafter transferred into Immobilon-P Transfer Membranes (Merck Millipore, Billerica, MA, USA). Each membrane was blocked in 5% non-fat dry milk in phosphate-buffered saline with Tween-20 (PBST; 8 mM Na2HPO4, 0.15 M NaCl, 2 mM KH2PO4, 3 mM KCl, 0.05% Tween-20, pH 7.4) for 1 h. The membranes were then incubated at 4°C overnight with primary antibodies against p-EGFR (cat. no. GTX61535), EGFR (cat. no. GTX100448), p-ERK (cat. no. GTX59618), ERK (cat. no. GTX59618), p-JNK (cat. no. GTX52236), JNK (cat. no. GTX52360), p-p38 (cat. no. GTX48614), p38 (cat. no. GTX110720) (all 1:1,000 dilution), and β-actin (cat. no. GTX109639) (1:5,000 dilution) (GeneTex). Following washing with PBST, the membrane was incubated with appropriate anti-mouse (cat. No GTX213111-01)-rabbit (cat. no. GTX213110-01) HRP-conjugated secondary antibodies (1:10,000 dilution) for 1 h at room temperature. Proteins were visualized by enhanced chemiluminescence (Immobilon Western Chemiluminescent HRP Substrate; Merck Millipore) and using the LAS-4000 imaging system (Fuji, Tokyo, Japan), as previously described (38-40). The density of the immunoblots was analyzed using ImageJ (version 1.47; National Institutes of Health, Bethesda, MA, USA).

Statistical analysis. The values are presented as the mean ± standard deviation of 3 independent experiments. Comparisons between the drug-treated and -untreated groups were made using one-way analysis of variance followed by Dunnett's test using SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA). P<0.001 was considered to indicate a statistically significant difference.
Results

Effects of curcumin, cetuximab and combination treatment on the viability of cisplatin-resistant oral cancer CAR cells. The cytotoxicity of curcumin and cetuximab on CAR cells. The cells were cultured with various concentrations of curcumin (10, 20, 40 or 50 µM), or cetuximab (10, 20, 40 or 50 µg/ml), or 20 µg/ml cetuximab combined with 10, 20 or 40 µM curcumin, for 24 h. Cell viability was evaluated by MTT assay. The results demonstrated that curcumin markedly decreased the viability of CAR cells in a concentration-dependent manner, and the viability at 20, 40 and 50 µM was 87.1, 48.5 and 12.3%, respectively (Fig. 1A). It was also revealed that 20, 40 and 50 µg/ml cetuximab reduced CAR-cell viability to 85.8, 72.8 and 67.4%, respectively, another concentration-dependent effect (Fig. 1B). However, 10 µg/ml cetuximab demonstrated no significant inhibition. Thus, CAR cells were more sensitive to curcumin than that to cetuximab. The cells were treated with a combination of 20 µg/ml cetuximab and 0, 10, 20 and 40 µM curcumin for 24 h, and significant potentiation of cytotoxicity and synergy of CAR cells was demonstrated by viabilities of 83.7, 75.7, 70.3 and 38.6%, respectively (Fig. 1C). The combination index (C1) was 0.9, 0.8 and 0.6 at treatments of 20 µg/ml cetuximab and 10, 20 and 40 µM of curcumin, respectively, indicating the synergistic effects of cetuximab and curcumin. The results imply that a significant increase in cytotoxic effects was achieved with simultaneous administration of cetuximab and curcumin to CAR cells.

Effects of curcumin and cetuximab, alone or combined, on the morphology of CAR cells. Photomicrographs demonstrated that combined treatment resulted in cell shrinkage, cytoplasmic membrane blebbing and cell death, compared with exposure to 20 µg/ml cetuximab alone and untreated control (Fig. 2). Furthermore, combined treatment resulted in increased inhibition in viability of CAR cells compared with single-drug (cetuximab) treatment and untreated control (Fig. 2). These data indicated that concurrent exposure to cetuximab and curcumin synergistically induced apoptosis and reduced proliferation of CAR cells.

Effects of curcumin and cetuximab, alone or in combination, on caspase-3/-9-dependent apoptosis of CAR cells. To further examine whether the observed suppression of cell viability involved in apoptotic machinery, the cells were treated with 20 µg/ml cetuximab, or 40 µM curcumin, or both, for 24 h prior to determination of caspase-3 and caspase-9 activities. Individual treatment with cetuximab and curcumin induced 1.6- and 4.9-fold increases in caspase-3 activity compared with control, whereas combination treatment stimulated a 6.8-fold increase in the activity of caspase-3 of CAR cells (Fig. 3A). Similarly, caspase-9 activity was synergistically increased in CAR cells when treated with cetuximab and curcumin (6.0-fold increase; Fig. 3B). However, either curcumin or cetuximab alone stimulated more minor effects on caspase-9 activity, causing 1.5- and 3.6-fold increases in CAR cells. These results indicate the synergistic cytotoxicity of curcumin and cetuximab, and that the apoptotic mechanism was caspase-3/-9-dependent in CAR cells.

Discussion

Surgery and brachytherapy are the major therapies for oral cancer in the T1, T2 and artificial T3 groups (Tumor-Node-Metastasis classification) in clinical practice guidelines for head and neck cancer in Japan (42). Platinum-based chemotherapy (cisplatin or carboplatin) is used for advanced stage cancer (42,43). In 1978, cisplatin was approved by the Food and Drug Administration (FDA) for oral cancer treatment (44). Cisplatin is used for oral cancer chemotherapy and functions via direct reaction with cellular nucleophiles to achieve inter- and intra-stand DNA cross-links and protein cross-links with DNA and RNA (45). However, oral cancer cells have gained resistance to chemotherapeutic agents (46,47). Several molecular mechanisms are involved in cisplatin-resistance: i) Increased activity of transporter protein function (MDR1 or p-glycoprotein); ii) activated drug metabolism activity by enzymes; iii) decreased drug binding to DNA; iv) promoted ROS production; v) stimulated DNA repair; vi) increased tolerance to DNA damage; vii) altered transcription of target genes; viii) changes in cell cycle-associated events and ix) inhibition of cell death (46-48). Recently, EGFR has been demonstrated as an important therapeutic target in oral cancer, and it is expressed more highly in oral cancer tissue than in normal tissues (7,10). In addition, a correlation between high EGFR expression and radio-resistance was demonstrated in patients with oral cancer (49). Kuroda et al (50) demonstrated that cisplatin-resistance is associated with EGFR-mediated signaling in lung cancer A549 cells. Chemo-sensitivity to cisplatin was restored by an EGFR-selective tyrosine kinase inhibitor (AG1478) in A549 cells, suggesting that the EGFR inhibitor may be a therapy for cisplatin-resistance (50). To the best of our knowledge, this is the first study to report...
the synergistic inhibitory effect of cetuximab (an EGFR inhibitor) and curcumin in cisplatin-resistant human oral cancer cells.

Evidence indicates that the molecular mechanisms of cetuximab anticancer activity take 2 forms (51,52). Firstly, EGF binding to the EGFR extracellular domain to inhibit
subsequent receptor dimerization/activation and to induce EGFR degradation is inhibited. Secondly, antibody-dependent cellular cytotoxicity or complement-dependent cell-mediated cytotoxicity (51,52). Curcumin has been historically used in traditional Chinese medicine, and its anticancer effects on various types of solid cancers, such as colon cancer, multiple myeloma and pancreatic cancer have reached phase II and III clinical trials (53,54). Curcumin is also a potential therapeutic agent for the treatment of...
Hospital Funding for providing cetuximab (Erbitux) as a gift.

Department of Pharmacy, Hualien Tzu Chi Hospital (Taiwan)

The authors would like to thank Dr Hong-Yi Chiu of

a strategy to pursue in clinical trials.

drug, and the combination of cetuximab and curcumin may be

cisplatin-resistant oral cancer cells. With the results presented

mechanism results in a decreased activated EGFR level in

treatment is a novel therapeutic option for oral cancer treat

have been synthesized and tested in recent years (61,62).

bioavailability, and undergoes rapid metabolism (60).

functions. Although curcumin possesses powerful biological

activities, it does not reach the criteria of a good drug candi

increase in caspase-3 and caspase-9 activities in CAR cells.

However, the activities of caspase-3 and caspase-9 were
dramatically enhanced in CAR cells prior to treatment with
cetuximab combined with cisplatin on colon cancer growth. Cetuximab

ginantly decreased phosphorylation of EGFR and phosphorylated p38/p38 ratio at 30 µg/ml, but there was

no effect on the phosphorylated ERK/ERK ratio in colon
cancer HCT116 cells. The present study also demonstrated that
cetuximab treatment decreased the protein level of

phosphorylated EGFR and phosphorylated p38. In addition,

Li et al (59) demonstrated that the EGFR monoclonal anti

body, cetuximab, mildly evoked apoptosis of human vulvar squamous carcinoma A431 cells. This is consistent with

the present finding that cetuximab triggered a non-significant increase in caspase-3 and caspase-9 activities in CAR cells.

However, the activities of caspase-3 and caspase-9 were
dramatically enhanced in CAR cells prior to treatment with
cetuximab in combination with curcumin; or with exposure only to curcumin. The present results are also consistent with

previous studies (26,31) showing that curcumin is effec
tive against various types of cancer via intrinsic apoptotic

function. Although curcumin possesses powerful biological

activities, it does not reach the criteria of a good drug candidate because it lacks adequate water solubility and high

bioavailability, and undergoes rapid in vivo metabolism (60).

To overcome these limitations, novel forms of curcumin
targeting, including nanoparticles, liposomes, cyclodextrin

encapsulation, micelles and phospholipid complexes, have

been synthesized and tested in recent years (61,62).

In conclusion, combined cetuximab and curcumin
treatment is a novel therapeutic option for oral cancer treat

ment, exhibiting synergistic anti-proliferative activity. The mechanism results in a decreased activated EGFR level in
cisplatin-resistant oral cancer cells. With the results presented

in the present study, curcumin could be used as an adjuvant
drug, and the combination of cetuximab and curcumin may be a strategy to pursue in clinical trials.

Acknowledgements

The authors would like to thank Dr Hong-Yi Chiu of

Department of Pharmacy, Hualien Tzu Chi Hospital (Taiwan) for providing cetuximab (Erbitux) as a gift.

Funding

The present study was supported by China Medical University Hospital (grant no. DMR-107-1230).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

CFC, HJH and TDW conceived and designed the experiments; CFC, CCL, JHC, HYC, JSY, and CYL performed the experiments. CFC, CCL, JHC, and JSY analysed the data; CFC, HJH and TDW wrote and modified the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Horn D, Hess J, Freier K, Hoffmann J and Freudlsparger C: Targeting EGFR-P13K-AKT-mTOR signaling enhances radio-
sensitivity in head and neck squamous cell carcinoma. Expert Opin Ther Targets 19: 795-805, 2015.

2. Prince A, Aguirre-Ghizo J, Genden E, Posner M and Sikora A: Head and neck squamous cell carcinoma: New translational

therapies. Mt Sinai J Med 77: 684-699, 2010.

3. Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006.

4. Todd R and Wong DT: Epidermal growth factor receptor (EGFR) biology and human oral cancer. Histol Histopathol 14: 491-500,

1999.

5. Pickhard A, Siegl M, Baumann A, Huhn M, Wirth M, Reiter R, 

Rudelius M, Piontek G and Brockhoff G: The response of head

and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism. Oncotarget 5:

5428-5438, 2014.

6. Lin MC, Huang MJ, Liu CH, Yang TL and Huang MC: GALNT2 enhances migration and invasion of oral squamous cell carci

noma by regulating EGFR glycosylation and activity. Oral Oncol 50: 478-484, 2014.

7. Cassell A and Grandis JR: Investigational EGFR-targeted therapy in head and neck squamous cell carcinoma. Expert Opin

Investig Drugs 19: 709-722, 2010.

8. Hoch MA, Cousins K, Narrety R, Riley K and Hartranft M: Two cases of combination therapy with cetuximab, paclitaxel, and
cisplatin for advanced head and neck cancer. J Oncol Pharm Pract 107155217722406, 2017.

9. Liebig H, Güntcher G, Kolb M, Mozet C, Boehm A, Dietz A and Wichmann G: Reduced proliferation and colony formation of

head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways. Cancer Chemother

Pharmacol 79: 411-420, 2017.

10. Moon C, Chae YK and Lee J: Targeting epidermal growth factor receptor in head and neck cancer: Lessons learned from cetuxi

mab. Exp Biol Med (Maywood) 235: 907-920, 2010.

11. Astsaturov I, Cohen RB and Harari P: EGFR-targeting monocl

onal antibodies in head and neck cancer. Curr Cancer Drug

Targets 6: 691-710, 2006.

12. Dai W, Li Y, Zhou Q, Xu Z, Sun C, Tan X and Lu L: Cetuximab inhibits oral squamous cell carcinoma invasion and metastasis

via degradation of epidermal growth factor receptor. J Oral Pathol Med 43: 250-257, 2014.
13. Psyrris A, Seiwert TY and Jimeno A: Molecular pathways in head and neck cancer: EGFR, PI3K, and more. Am Soc Clin Oncol Educ Book: 246–255, 2013.

14. Wei G, Wolfert SB and Harari P: EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 7: 650–665, 2007.

15. Burgy M, Barthélémy P, Lefevre F, Dupret-Bories A, Truant P, Kørenbaum C, Flesch H, Bronner G and Borel C: Cetuximab-carboplatin-5-fluorouracil regimen in elderly patients with newly diagnosed, locoregionally advanced, locally recurrent, and/or metastatic head and neck squamous-cell carcinoma: A French retrospective survey. Oncology 11: 13-17, 2017.

16. Guigay J, Even C, Mayache-Badis L, Debah M, Saada-Bouzid E, Yao T, Deschamps J, Fanet J, Leghzed N and Michel C: Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TCP) as first-line treatment followed by cetuximab maintenance. Oral Oncol 68: 114–118, 2017.

17. Unlu A, Nayir E, Dogukan Kalenderoglu M, Kirca O and Ozdogan M: Curcumin (Tumeric) and cancer. J BUON 21: 1050-1060, 2016.

18. He Y, Yue Y, Zheng X, Zhang K, Chen S and Du Z: Curcumin, inflammation, and chronic diseases: How are they linked? Molecules 20: 9813-9213, 2015.

19. Wang J and Jiang YF: Natural compounds as anticancer agents: Experimental evidence. World J Exp Med 2: 45-57, 2012.

20. Chen ZF and Liang H: Progress in TCM metal-based antitumor agents. Anticancer Agents Med Chem 10: 412-423, 2010.

21. Pandima Devi K, Rajavel T, Daglia M, Nabavi SF, Bishaye A and Nabavi SM: Targeting miRNAs by polyphenols: Novel therapeutics strategy for cancer. Semin Cancer Biol 40: 146-157, 2017.

22. Owen HC, Appiah S, Hasan N, Ghali L, Elayat G and Bell C: Redox chemotherapy and cisplatin-induced ototoxicity: The role of mitochondrial and nuclear response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TCP) as first-line treatment followed by cetuximab maintenance. Oral Oncol 68: 114–118, 2017.

23. Karimian MS, Pirro M, Johnston TP, Majeed M and Sahebkar A: Curcumin and endothelial function: Evidence and mechanisms of protective effects. Curr Pharm Des 23: 2462-2473, 2017.

24. Jha A, Mohapatra PP, AlHarbi SA and Jahan N: Curcumin: Not so spicy after all. Mini Rev Med Chem 17: 1425-1434, 2017.

25. Vander Broek R, Snow GE, Chen Z and Van Waes C: Newly synthesized quinazolinone HMJ-38 suppresses angiogenic responses and triggers human umbilical vein endothelial cell apoptosis through p53-modulated Fas/Death receptor signaling. Toxicol Appl Pharmcol 269: 150-162, 2013.

26. Ma YS, Weng SW, Lin MW, Lu CC, Chiang JH, Yang JS, Lai KC, Lin JP, Tang NY, Lin JG and Chung JG: Antitumor effects of emodin on LS1034 human colon cancer cells in vitro and in vivo: Roles of apoptotic cell death and LS1034 tumor xenografts model. Food Chem Toxicol 50: 1271-1278, 2012.

27. Huang WW, Chuu YJ, Fan MJ, Lu HF, Yeh HF, Li KH, Chen PY, Chung JG and Yang JS: Kaempferol induced apoptosis via endoplasmic reticulum stress and mitochondria-dependent pathway in human osteosarcoma U-2 OS cells. Mol Nutr Food Res 54: 1585-1599, 2010.

28. Grossi V, Pesciero A, Tezil T and Simone C: p38alp MAPK pathway: A key factor in colorectal cancer therapy and chemoresistance. World J Gastroenterol 20: 9744-9758, 2014.

29. Naka K, Ishayashi Y, Ochiai H, Ojiri H, Kimata Y, Kodaira T, Nagao T, Nakashima T, Fujii T, Fujii H, et al: Japanese clinical practice guideline for head and neck cancer. Auris Nasus Larynx 44: 375-380, 2017.

30. Brockstein BE and Vokes EE: Oral chemotherapy in head and neck cancer. Drugs 59 (Suppl 3): S91-S97, 1999.

31. Köberle B, Tomicic MT, Uzunova S and Kaina B: Cisplatin resistance: Preclinical findings and clinical implications. Biochim Biophys Acta 1806: 172-182, 2010.

32. Carlson L, Bratman SV, Su LL and Spellman A: The cisplatin total dose and concomitant radiation in locoregionally advanced head and neck cancer: Any recent evidence for dose efficacy? Curr Treat Options Oncol 18: 39, 2017.

33. Wang C, Liu XQ, Hou JS, Wang JN and Huang HZ: Molecular mechanisms of chemoresistance in oral cancer. Chin J Dent Res 19: 28-33, 2016.

34. Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 743: 363-374, 2014.

35. Brozovic A: The relationship between platinum drug resistance and epithelial-mesenchymal transition. Arch Toxicol 91: 605-619, 2017.

36. Alorabi M, Shonka NA and Ganti AK: EGFR monoclonal antibodies in locally advanced head and neck squamous cell carcinoma: What is their current role? Crit Rev Oncol Hematol 99: 170-179, 2016.

37. Kuroda H, Takeno M, Murakami S, Miyazawa N, Kaneko T and Ishigatsubo Y: Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases nonprogrammed death (necrosis) in human glioblastoma multiforme DBTRG-05MG cells through MPT pore opening and ATP decline. Mol Nutr Food Res 58: 2146-2156, 2014.

38. Chung JH, Yang JS, Lu CC, Hou MJ, Chang SJ, Lee TH and Chung JG: New drug development for patients with EGFR-TKI-resistant advanced NSCLC: Roles of anti-EGFR therapy and targeted therapy in combination therapy. Int J Oncol 45: 1451-1463, 2019.

39. Tao Y, Deschamps F, Janot F, Lezghed N and Michel C: Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TCP) as first-line treatment followed by cetuximab maintenance. Oral Oncol 68: 114–118, 2017.

40. Lu CC, Chang PL, Liu CC, Wu CC, Yang JS, Lai KC, Lin JP, Tang NY, Lin JG and Chung JG: Antitumor effects of emodin on LS1034 human colon cancer cells in vitro and in vivo: Roles of apoptotic cell death and LS1034 tumor xenografts model. Food Chem Toxicol 50: 1271-1278, 2012.

41. Wang J, Yue Y, Wang J, Hon SY and Hu CY: Cetuximab-carboplatin-5-fluorouracil regimen in elderly patients with newly diagnosed, locoregionally advanced, locally recurrent, and/or metastatic head and neck squamous-cell carcinoma: A French retrospective survey. Oncology 11: 13-17, 2017.

42. Lu CC, Yang JS, Chiang JH, Hou MJ, Lin KL, Lee TH and Chung JG: Cell death caused by quinazolinone HMJ-38 challenge in oral carcinoma CAL-27 cells: Dissections of endoplasmic reticulum stress, mitochondrial dysfunction and tumor xenografts. Biochim Biophys Acta 1840: 2310-2320, 2014.

43. Xu Y, Xiu Y, Diao Y, Lu C, Fu J, Luo L and Yin Z: Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells. PLoS One 6: e29019, 2011.

44. Lu CC, Huang BR, Lu YJ and Yen GC: Ursolic acid triggers nonprogrammed death (necrosis) in human glioblastoma multiforme DBTRG-05MG cells through MPT pore opening and ATP decline. Mol Nutr Food Res 58: 2146-2156, 2014.

45. Chung JH, Yang JS, Lu CC, Hou MJ, Chang SJ, Lee TH and Chung JG: New drug development for patients with EGFR-TKI-resistant advanced NSCLC: Roles of anti-EGFR therapy and targeted therapy in combination therapy. Int J Oncol 45: 1451-1463, 2019.

46. Ji JL, Huang XF, and Zhu HL: Curcumin and its formulations: Novel chemopreventive agents. Curr Treat Options Oncol 18: 39, 2017.

47. Wang C, Liu XQ, Hou JS, Wang JN and Huang HZ: Molecular mechanisms of chemoresistance in oral cancer. Chin J Dent Res 19: 28-33, 2016.
55. Qadir MI, Naqvi ST and Muhammad SA: Curcumin: A polyphenol with molecular targets for cancer control. Asian Pac J Cancer Prev 17: 2735-2739, 2016.

56. Weisberg S, Leibel R and Tortorello DV: Proteasome inhibitors, including curcumin, improve pancreatic β-cell function and insulin sensitivity in diabetic mice. Nutr Diabetes 6: e205, 2016.

57. Lee JY, Lee YM, Chang GC, Yu SL, Hsieh WY, Chen JJ, Chen HW and Yang PC: Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: The versatile adjuvant for gefitinib therapy. PLoS One 6: e23756, 2011.

58. Son DJ, Hong JE, Ban JO, Park JH, Lee HL, Gu SM, Hwang JY, Jung MH, Lee DW, Han SB and Hong JT: Synergistic inhibitory effects of cetuximab and cisplatin on human colon cancer cell growth via inhibition of the ERK-dependent EGF receptor signaling pathway. Biomed Res Int 2015: 397563, 2015.

59. Li X, Lu Y, Pan T and Fan Z: Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 6: 1066-1077, 2010.

60. Douglass BJ and Clouatre DL: Beyond yellow curry: Assessing commercial curcumin absorption technologies. J Am Coll Nutr 34: 347-358, 2015.

61. Chang LC, Hsieh MT, Yang JS, Lu CC, Tsai FJ, Tsao JW, Chiu YJ, Kuo SC and Lee KH: Effect of bis(hydroxymethyl) alkanoate curcuminoid derivative MTH-3 on cell cycle arrest, apoptotic and autophagic pathway in triple-negative breast adenocarcinoma MDA-MB-231 cells: An in vitro study. Int J Oncol 52: 67-76, 2018.

62. Hsieh MT, Chang LC, Hung HY, Lin HY, Shih MH, Tsai CH, Kuo SC and Lee KH: New bis(hydroxymethyl) alkanoate curcuminoid derivatives exhibit activity against triple-negative breast cancer in vitro and in vivo. Eur J Med Chem 131: 141-151, 2017. 

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.